Valion Bio, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On August 31, 2026, 3i LP closed a $7.74M investment in Valion Bio: $100K in Series B Preferred Shares (100 shares) with warrants for 3,077 common shares at $3.62/share; and $7.637M in Series C Preferred Shares (7,637 shares) with warrants for 1,053,969 common shares at $3.62/share. Of this amount, $6.137M satisfied overdue cash true-up obligations, $100K covered legal fees, and $1.5M was paid to the company. Separately, Lisa Wolf was promoted from CFO to President and COO (retaining CFO duties) following Michael K. Handley's departure as CEO; board directors Jared Malbin and Thomas Jensen were appointed.
Why this rating
Investment equals 194% of company's $4M market cap; provides near-term liquidity ($1.5M cash). Leadership restructuring under going-concern pressure is material but Wolf's appointment suggests investor confidence. Dilutive warrant package (1.06M shares) and overdue obligations indicate financial stress, offsetting positive aspects.
Price action (we called it positive)
before filing · preread $3.26 ▼ 8.68% | at our read · unknown $3.57 | +10 min · unknown $3.57 ▲ 0.00% | +30 min · unknown $3.57 ▲ 0.00% | +1 hr · unknown $3.57 ▲ 0.00% | +4 hrs pending |
The stock had already moved +9.51% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.